Preventing Dementia Through 4P Medicine: A Revolutionary Approach to Brain Health

Dementia presents one of the most significant health and societal challenges of our time. With populations ageing across the globe, the number of people living with dementia is escalating rapidly, projected to potentially triple worldwide by 2050 [1, 2]. This brings not only profound personal costs for individuals experiencing cognitive decline but also immense emotional and practical burdens for their families and carers. The economic impact on healthcare and social care systems is already substantial and growing unsustainably. Recognizing this, governments, including the UK, are increasingly focusing on proactive health strategies. Recent initiatives emphasise the potential of predictive and personalised medicine, harnessing genomics and data analytics to anticipate risk and tailor interventions [3, 4]. This aligns perfectly with the principles of 4P Medicine (Predictive, Preventive, Personalized, Participatory). By adopting this framework for dementia, we can move beyond reactive care, empowering individuals with the knowledge and tools to understand their risk, take proactive steps to protect their brain health, receive care tailored to their unique biology and circumstances, and actively participate in their journey, ultimately aiming to reduce the devastating burden of this condition.

Predictive: Knowing and Understanding Your Risk

Understanding who is at risk, and why, is the cornerstone of effective prevention. While age remains the single biggest non-modifiable risk factor, our understanding of genetic and biological predictors has advanced significantly, alongside the identification of numerous lifestyle and environmental factors we can influence.

The APOE Gene: A Key Genetic Clue

The Apolipoprotein E (APOE) gene is the most significant and well-studied common genetic risk factor for late-onset Alzheimer's disease. It provides instructions for making a protein crucial for transporting lipids (like cholesterol) in the blood and brain, playing vital roles in neuronal repair, synaptic function, and the clearance of amyloid-beta (Aβ) – the protein that forms plaques in Alzheimer's disease.

There are three main versions (alleles): ε2, ε3, and ε4.

• APOE ε3: The most common, considered neutral for risk.
• APOE ε2: Relatively rare, appears somewhat protective.
• APOE ε4: Present in about 15-25% of the population, this allele significantly increases Alzheimer's risk and lowers the age of onset. One copy increases risk severalfold; two copies increase it substantially more. The ε4 protein is thought to be less efficient at clearing Aβ, may promote Aβ aggregation, and potentially fosters detrimental inflammation and lipid disruption in the brain [5, 6].
• Crucially, APOE ε4 is a risk factor, not a guarantee. Many ε4 carriers never develop dementia, and many with dementia lack the ε4 allele. This highlights that genetics don't determine destiny, and modifying other risk factors is vital, even for ε4 carriers [2].

Phosphorylated Tau (p-tau217): A Window into Disease Biology

Biomarkers offer insights into active disease processes. Among the most promising, especially via blood tests, is p-tau217. Tau protein normally stabilizes neuron skeletons (microtubules). In Alzheimer's, it gets hyperphosphorylated (excess phosphate groups added), detaches, and aggregates into neurofibrillary tangles, disrupting cell function.

P-tau217 refers to tau phosphorylated specifically at the threonine-217 site. Research shows blood p-tau217 levels are:

• Highly Specific for Alzheimers Disease: Effectively distinguishing Alzheimer's from other neurodegenerative diseases [7].
• Correlated with Pathology: Strongly correlating with both amyloid plaques and tau tangles measured by PET scans [7, 8].
• Early Indicators: Levels rise early, potentially years before symptoms, tracking with initial amyloid build-up [8].
• Potential Utility: Making blood p-tau217 a promising biomarker for earlier diagnosis, monitoring progression, and clinical trial selection [9]. While not yet standard clinical practice, its development represents a major advance towards accessible, biologically precise diagnostics.

Looking in to prevention: The 14 Modifiable Risk Factors

Beyond genetics and specific biomarkers, the 2024 Lancet Commission identifies 14 potentially modifiable risk factors. Addressing these throughout life is crucial. To understand the impact of these factors at a population level, scientists use a measure called the Population Attributable Fraction (PAF).

What is PAF? Put simply, the PAF estimates the percentage of dementia cases within a population that could potentially be avoided if a specific risk factor was completely eliminated. It considers both how strongly the factor increases risk and how common it is. The Weighted PAF values below are adjusted to account for the common overlap between risk factors (e.g., people often have more than one).

The Commission's analysis suggests that eliminating these 14 factors could theoretically prevent or delay nearly half (an estimated 45.3%) of dementia cases worldwide [2].

Table: 14 Potentially Modifiable Risk Factors for Dementia and their Estimated Population Impact (Weighted PAF)
(Data synthesized by the Lancet Commission 2024 [2])

*Calculated by Lancet Commission 2024. †Prevalence from HUNT study; RR assumes generic cardiovascular link.
(Note: Risk factors often cluster, particularly with socioeconomic disadvantage, which needs consideration in prevention strategies [2]).

Preventive: Building a Resilient Brain Throughout Life

Knowing the risks empowers us to act. The powerful message from the 2024 Lancet Commission is that "it is never too early or too late" to take steps to reduce dementia risk [2]. Adopting a multi-faceted approach, targeting several risk factors, offers the best chance [2, 10]. Among the 14 factors, the evidence linking sensory loss to dementia risk is particularly compelling and warrants a closer look.

Hearing Loss: Listening to the Evidence

Untreated hearing loss, especially from midlife, is a major modifiable risk factor, contributing an estimated 7% to the overall potential prevention figure [2]. The link is supported by strong observational data showing a consistent association between hearing impairment and increased dementia risk [Ref: eg., Loughrey 2018, Yu 2024]. Recent clinical trial evidence adds crucial weight.

• Potential Mechanisms: Why might hearing loss impact dementia risk? Several theories exist [11, 2]:
  • Increased Cognitive Load: The brain constantly strains to decode diminished auditory signals, diverting resources from memory and thinking. This chronic effort may tax cognitive reserves over time.
  • Changes in Brain Structure/Function: Reduced auditory input may lead to accelerated atrophy or functional changes in brain regions involved in processing sound and also supporting wider cognitive functions.
  • Reduced Social Engagement: Difficulty following conversations can lead individuals to withdraw from social situations, reducing vital cognitive stimulation and increasing risks of isolation, loneliness, and depression – all independent risk factors for dementia.
• Trial Insights: While numerous observational studies highlight the link, the ACHIEVE randomised controlled trial (RCT) provided key insights into intervention [12]. It compared the effect of providing hearing aids versus standard health education on cognitive decline over 3 years. Overall, there was no significant difference in the primary outcome across the entire study group. However, a critical pre-planned subgroup analysis focused on participants who entered the trial from an existing ageing study (ARIC). This group was, on average, older and had more baseline cardiovascular risk factors, placing them at higher risk for cognitive decline. Within this specific higher-risk group, the use of hearing aids led to a statistically significant 48% reduction in the rate of global cognitive decline over 3 years compared to the control group receiving only health education.
• Takeaway: The ACHIEVE trial suggests that while hearing aids might not dramatically alter cognitive trajectories for all healthy older adults over a 3-year period, they appear highly beneficial for those already facing an elevated risk of dementia. This strengthens the case for treating hearing loss as a key preventive strategy, particularly in vulnerable populations. Making hearing assessment and hearing aids more accessible should be a public health priority [2, 12].

Vision Loss: Seeing the Connection

Untreated vision loss is now recognised by the Lancet Commission as another important modifiable risk factor, estimated to contribute 2% to potentially preventable cases [2].

• Potential Mechanisms: Similar hypotheses apply as for hearing loss [2, 13]:
  • Reduced Sensory Input: Decreased quantity or quality of visual information reaching the brain could impact brain structure and function long-term.
  • Reduced Engagement: Impaired vision can significantly curtail participation in cognitively stimulating activities like reading, hobbies, or navigating complex environments. Difficulty recognising faces can also lead to social withdrawal. Reduced mobility due to fear of falls can decrease physical activity.
  • Shared Pathologies: Certain conditions causing vision loss, notably diabetes (leading to diabetic retinopathy) and underlying vascular disease, are also direct risk factors for dementia itself.
• Observational Strength: Robust evidence comes from large cohort studies and meta-analyses. Visual impairment is consistently associated with around a 40-50% increased risk of incident dementia [13, 14]. Specific conditions like cataracts and diabetic retinopathy have been linked to increased risk [14]. Significantly, multiple large cohort studies have now reported that cataract surgery is associated with a substantially reduced risk of subsequently developing dementia compared with individuals with cataracts who do not undergo surgery [15, 16].
• Takeaway: While large-scale RCTs specifically testing vision correction for dementia prevention are currently lacking, the consistent epidemiological evidence, the plausible mechanisms, and the particularly strong signal from the cataract surgery studies make a compelling case. Addressing vision impairment through regular eye checks and appropriate correction (glasses, contact lenses, surgery) is likely important not just for eye health, but for brain health too [2]. Ensuring equitable access to vision care is therefore an important component of a comprehensive dementia prevention strategy.

Other Key Preventive Pillars [2]:

• Heart & Vascular Health: Manage hypertension, treat high LDL cholesterol (new factor), manage diabetes and obesity (especially midlife). Stop smoking (cessation reduces risk).
• Mind & Mood: Prioritize education and lifelong cognitive activity. Treat depression effectively (stronger evidence now).
• Lifestyle: Stay physically active and socially engaged. Limit excessive alcohol. Protect your head from traumatic brain injury (helmets, safer sports practices).
• Environment: Advocate for and support policies reducing air pollution.

Personalised: Tailoring Your Brain Health Strategy

A one-size-fits-all approach isn't optimal. Personalisation means tailoring prevention and treatment based on an individual's specific risks, biology, lifestyle, and stage of cognitive health. This could mean focusing prevention on your key risks (e.g., intensive BP management if hypertensive) – strategies which work even for APOE ε4 carriers [2].

In treatment, personalisation is exemplified by new anti-amyloid therapies (Lecanemab, Donanemab) which require biomarker confirmation (amyloid positivity via PET or CSF) before use [2, 17, 18].

• Anti-Amyloid Therapies: A Step Forward with Caveats [2]:
  • These drugs show modest efficacy in slowing cognitive decline over 18 months in people with early Alzheimer's disease (MCI or mild dementia) who have confirmed amyloid pathology.
  • They are not cures and come with significant risks of side effects (ARIA - brain swelling or bleeding), requiring intensive MRI monitoring. Risk is higher for APOE ε4 carriers.
  • They involve considerable burden (regular infusions) and cost, with major healthcare resource implications.
  • Long-term effectiveness and safety are unknown.
  • Trial participants were generally healthier than many real-world patients, limiting generalisability. Shared decision-making, fully informing patients of risks, benefits, costs, and uncertainties, is essential.

Exploring Comprehensive Personalised Protocols:

In the pursuit of more personalised approaches, particularly aiming to improve or stabilise cognitive function in those already experiencing decline, various comprehensive protocols have emerged. One widely discussed example is the Bredesen Protocol, also known as ReCODE (Reversal of Cognitive Decline) [19, 20].

• Concept: This protocol operates on the premise that cognitive decline, particularly in Alzheimer's disease, often results from a combination of metabolic and biological factors that can differ between individuals. It utilises extensive metabolic and genetic testing to identify potential contributors in a given person, such as inflammation, insulin resistance, toxin exposure, nutrient and hormonal imbalances (often classified into Bredesen's 'subtypes' like Inflammatory, Glycotoxic, Atrophic, Toxic, Vascular). Based on these individual profiles, a multi-component program is developed, often incorporating:
  • Highly specific dietary adjustments (e.g., promoting metabolic flexibility, sometimes involving ketogenic principles).
  • Targeted nutritional support based on identified needs.
  • Strategies for stress management.
  • Tailored exercise recommendations.
  • Sleep optimisation techniques.
  • Cognitive training exercises.
  • Methods to address potential toxin exposures.
• Published Findings and Current Status: The appeal of this protocol lies in its comprehensive, systems-biology approach, aiming to address multiple factors simultaneously. Several publications, including case series and pilot studies involving individuals with Mild Cognitive Impairment (MCI) or early dementia, have reported improvements or stabilisation in cognitive function among participants following the protocol [21, 22]. For instance, one pilot study (n=25) reported statistically significant improvements in MoCA and CNS Vital Signs cognitive scores over 9 months, with 84% of participants showing cognitive improvement and no serious adverse events recorded [22]. These reports suggest that such a multi-pronged, personalised approach may hold potential for some individuals.
• Need for Further Research: As with many complex, multi-component interventions, the scientific evaluation is ongoing. The current published evidence largely consists of observational data and initial feasibility or proof-of-concept studies. While these studies provide valuable preliminary insights, the scientific community generally looks towards larger, randomised controlled trials (RCTs) to definitively establish efficacy, understand the magnitude of any effect compared to control conditions (including placebo effects), and determine which components of the protocol are most crucial. Such trials are essential to confirm the initial findings, understand the long-term impacts, and assess how broadly applicable the results might be across different populations and stages of cognitive impairment. The protocol's comprehensive nature, involving significant lifestyle changes and often supplementation, also requires considerable commitment from participants.
• Conclusion on Personalised Protocols: The concept of personalised, multi-factorial intervention aligns well with the direction of 4P medicine. Protocols like Bredesen/ReCODE represent an active area of investigation exploring this concept for cognitive decline. Continued rigorous research, including well-designed controlled trials, will be important to fully understand their potential role, effectiveness, and place within the broader landscape of dementia care and prevention. It is worth noting that multi-domain prevention trials, like FINGER, have established RCT evidence for protecting cognitive function in individuals identified as being at higher risk [10]. Current clinical practice emphasizes evidence-based management of established risk factors and validated treatments, while research continues to explore novel personalised approaches.

Participatory: Taking an Active Role in Your Cognitive Future

The final 'P' underscores that you are the most important member of your brain health team. This means:

• Being Informed: Understanding your personal risks and the evidence-based actions you can take.
• Knowing Your Numbers: Tracking key health indicators like blood pressure and cholesterol.
• Partnering with Healthcare Professionals: Actively discussing your risks, lifestyle goals, sensory health (hearing/vision), mood, and making informed, shared decisions about prevention and any potential treatments. This is vital for complex decisions like considering anti-amyloid therapy.
• Engaging in Healthy Behaviours: Consistently applying the preventive strategies discussed.
• Advocating: Supporting brain-healthy communities and public health policies (e.g., clean air initiatives, accessible education, healthcare and support for people and families affected by dementia).

Conclusion: Hope, Action, and the Path Forward

The 4P medicine framework provides a powerful, proactive, and hopeful roadmap for confronting dementia. The latest evidence, particularly the 2024 Lancet Commission report, reinforces that a significant portion of dementia risk – potentially nearly half – is linked to modifiable factors throughout our lives [2]. There is real potential to change the trajectory of dementia through ambitious prevention efforts.

This requires a dual approach: empowering individuals with the knowledge and tools to make brain-healthy choices ("Never too early or too late"), while simultaneously implementing supportive public health policies that make those choices easier and more equitable for everyone. By embracing prediction, prevention, personalisation, and participation, we can collectively work towards a future with less dementia and more years of healthy cognitive life. Start today – make one positive change, talk to your doctor about your brain health, stay informed, and become an active participant in safeguarding your cognitive future.

References

1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022; 7: e105–25.
2. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 2024; Published Online July 31. https://doi.org/10.1016/S0140-6736(24)01296-0
3. Department of Health and Social Care. Genome UK: the future of healthcare. 2020.
4. NHS England. The NHS Long Term Plan. 2019.
5. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9: 106–18.
6. Safieh M, et al. Alzheimer's disease: an update on the genetics and use of APOE genotyping. J Alzheimers Dis Rep 2019; 3: 145–56.
7. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020; 324: 772–81.
8. Milà-Alomà M, Ashton NJ, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease. Nat Med 2022; 28: 1797–801.
9. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med 2021; 27: 954–63.
10. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 385: 2255–63.
11. Griffiths TD, Lad M, Kumar S, et al. How can hearing loss cause dementia? Neuron 2020; 108: 401–12.
12. Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet 2023; 402: 786–97.
13. Shang X, Zhu Z, Wang W, Ha J, He M. The association between vision impairment and incidence of dementia and cognitive impairment: a systematic review and meta-analysis. Ophthalmology 2021; 128: 1135–49.
14. Kuźma E, Littlejohns TJ, Khawaja AP, Llewellyn DJ, Ukoumunne OC, Thiem U. Visual impairment, eye diseases, and dementia risk: a systematic review and meta-analysis. J Alzheimers Dis 2021; 83: 1073–87.
15. Lee CS, Gibbons LE, Lee AY, et al. Association between cataract extraction and development of dementia. JAMA Intern Med 2022; 182: 134–41.
16. Ma LZ, Zhang YR, Li YZ, et al. Cataract, cataract surgery, and risk of incident dementia: a prospective cohort study of 300,823 participants. Biol Psychiatry 2023; 93: 810–19.
17. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med 2023; 388: 9–21.
18. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023; 330: 512–27.
19. Bredesen DE. Reversal of cognitive decline: A novel therapeutic program. Aging (Albany NY) 2014; 6: 707–17.
20. Bredesen DE, Amos EC, Canick J, et al. Reversal of cognitive decline: 100 patients. J Alzheimers Dis Parkinsonism 2016; 6: 26.
21. Bredesen DE, Sharlin K, Jenkins D, et al. Reversal of Cognitive Decline: A Novel Therapeutic Program. J Alzheimers Dis Parkinsonism 2018; 8: 450.
22. Toups K, Hathaway A, Gordon E, et al. Precision Medicine Approach to Alzheimer's Disease: Successful Pilot Project. J Alzheimers Dis 2022; 88: 1405–25.